Novel Manufacturing Technologies for the Production of Patient-Centric Drug Products
暂无分享,去创建一个
[1] D. Grobbee,et al. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. , 2013, American heart journal.
[2] Maryann M Fulton,et al. Polypharmacy in the elderly: A literature review , 2005, Journal of the American Academy of Nurse Practitioners.
[3] C. Cannon. Can the polypill save the world from heart disease? , 2009, The Lancet.
[4] J. M. Casado. The history of geriatric medicine. The present: Problems and opportunities , 2012 .
[5] D. V. van Riet-Nales,et al. Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: a systematic literature review. , 2010, Clinical therapeutics.
[6] M. Orlu-Gul,et al. ommentary eeting commentary — “ Medicines for older adults : Learning from ractice to develop patient centric drug products ” , 2013 .
[7] Hiroto Ito,et al. What Should We Do to Improve Patients' Adherence? , 2013 .
[8] C. Tuleu,et al. Public engagement workshop: how to improve medicines for older people? , 2014, International journal of pharmaceutics.
[9] C. Tuleu,et al. Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations , 2014, Drugs.
[10] E. McAuley,et al. Predictors of adherence to behavior change interventions in the elderly. , 2000, Controlled clinical trials.
[11] S. Yusuf,et al. The Indian Polycap Study (TIPS) – Authors' reply , 2009, The Lancet.
[12] L. Osterberg,et al. Adherence to medication. , 2005, The New England journal of medicine.
[13] J. Baeyens,et al. Design of pharmaceutical products to meet future patient needs requires modification of current development paradigms and business models , 2014, Zeitschrift für Gerontologie und Geriatrie.
[14] Francesca Cerreta,et al. Adherence measurement systems and technology for medications in older patient populations , 2012 .
[15] D. Wald,et al. The Polypill in the prevention of cardiovascular disease. , 2011, Preventive medicine.
[16] Allan Clarke,et al. Development of Liquid Dispensing Technology for the Manufacture of Low Dose Drug Products , 2017 .
[17] R. Doughty,et al. IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care. , 2011, Contemporary clinical trials.
[18] A. Zimmer,et al. Geriatric drug therapy: Neglecting the inevitable majority , 2010, Ageing Research Reviews.
[19] Jack Y. Zheng. Formulation and Analytical Development for Low-Dose Oral Drug Products , 2009 .
[20] J. Seville,et al. A comparative study of compaction properties of binary and bilayer tablets , 2009 .
[21] Mridula Nair,et al. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable , 2007, Expert opinion on drug safety.
[22] M. Vaduganathan,et al. Expanding the scope of the "polypill" to heart failure. , 2013, Journal of cardiac failure.
[23] S. Kagan,et al. Adherence and oral agents with older patients. , 2011, Seminars in oncology nursing.
[24] Jennifer G. Robinson,et al. A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. , 2005, The American journal of cardiology.
[25] S. Wollowitz. Managing high‐potency active pharmaceutical ingredients—A drug sponsor's guide , 2010 .
[26] Jack Y. Zheng. Challenges and Strategies in Formulation Development of Oral Solid Low‐Dose Drug Products , 2008 .
[27] Yu Heng Kwan,et al. Medication adherence in the elderly , 2016 .
[28] R. Sulkava,et al. Patterns of Drug Use and Factors Associated with Polypharmacy and Excessive Polypharmacy in Elderly Persons , 2009, Drugs & aging.
[29] I. Gavras,et al. Fixed-drug combinations as first-line treatment for hypertension. , 2006, Progress in cardiovascular diseases.
[30] M. Law,et al. The Indian Polycap Study (TIPS) , 2009, The Lancet.
[31] K. Masaki,et al. Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. , 2012, Journal of the American Medical Directors Association.
[32] A. Mohammed,et al. The impact of ageing on the barriers to drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[33] S. Leeder,et al. Duration of initial antihypertensive prescription and medication adherence: a cohort study among 203,259 newly diagnosed hypertensive patients. , 2015, International journal of cardiology.
[34] J. Remon,et al. Tablet-splitting: a common yet not so innocent practice. , 2011, Journal of advanced nursing.
[35] V. Fuster,et al. The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives. , 2011, American heart journal.
[36] S. Jain,et al. Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance , 2001, Postgraduate medical journal.
[37] C. Sharkness,et al. The patient's view of hypertension and compliance. , 1992, American journal of preventive medicine.
[38] G. Sergi,et al. Polypharmacy in the Elderly , 2011, Drugs & aging.
[39] Victor E. Kane,et al. Process Capability Indices , 1986 .
[40] Betty L. Elder,et al. The Role of a Self-Directed Technology to Improve Medication Adherence in Heart Failure Patients , 2014 .
[41] Michael J Blaha,et al. Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis). , 2014, Journal of the American College of Cardiology.
[42] J Breitkreutz,et al. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. , 2012, International journal of pharmaceutics.
[43] L. Treiber,et al. Intervening at the Intersection of Medication Adherence and Health Literacy , 2014 .
[44] Michel C. A. Klein,et al. Intelligent mobile support for therapy adherence and behavior change , 2014, J. Biomed. Informatics.
[45] V. Fuster,et al. Polypill and global cardiovascular health strategies. , 2011, Seminars in thoracic and cardiovascular surgery.
[46] R. Balkrishnan,et al. Predictors of medication adherence in the elderly. , 1998, Clinical therapeutics.
[47] L. Ring,et al. "I don't know how many of these [medicines] are necessary.." - a focus group study among elderly users of multiple medicines. , 2009, Patient education and counseling.
[48] Helen E. Smith,et al. Measuring the adherence to medication of elderly patients with heart failure: is there a gold standard? , 2010, International journal of cardiology.
[49] V. Fuster,et al. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. , 2014, Journal of the American College of Cardiology.
[50] Upkar Varshney,et al. Smart medication management system and multiple interventions for medication adherence , 2013, Decis. Support Syst..
[51] A. Rodgers,et al. The Efficacy and Tolerability of ‘Polypills’: Meta-Analysis of Randomised Controlled Trials , 2012, PloS one.
[52] S. Yusuf,et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial , 2009, The Lancet.